|
業務類別
|
Biotechnology |
|
業務概覽
|
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGENDPhase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform. |
| 公司地址
| 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1 |
| 電話號碼
| +1 514 332-4888 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.engene.com |
| 員工數量
| 82 |
| Mr. Lee G. Giguere |
Chief Legal Officer and Corporate Secretary |
-- |
08/05/2026 |
| Mr. Ronald Harold Wilfred Cooper |
President, Chief Executive Officer and Director |
美元 700.00K |
08/05/2026 |
| Mr. Ryan Daws |
Chief Financial Officer and Principal Accounting Officer |
美元 473.00K |
15/06/2026 |
| Ms. Jill Buck |
Chief Development Officer |
-- |
08/05/2026 |
| Dr. Anthony Tzeyew Cheung, PhD |
Chief Scientific Officer |
-- |
08/05/2026 |
| Ms. Joan Connolly |
Chief Technology Officer |
-- |
08/05/2026 |
| Ms. Kathleen Richton |
Senior Vice President, Finance; Chief Financial Officer and Chief Accounting Officer |
-- |
15/06/2026 |
| Mr. Matthew Boyd |
Chief Regulatory Officer |
-- |
08/05/2026 |
| Dr. Alexander Julian Nichols, PhD |
Chief Strategy Officer and Chief Operations Officer |
-- |
08/05/2026 |
| Ms. Amy Pott |
Chief Global Commercialization Officer |
-- |
08/05/2026 |
|
|
| Mr. Ronald Harold Wilfred Cooper |
President, Chief Executive Officer and Director |
08/05/2026 |
| Mr. Paul J. Hastings |
Independent Director |
08/05/2026 |
| Dr. Richard M. Glickman,L.L.D. |
Chairman of the Board |
08/05/2026 |
| Mr. Gerald Brunk |
Independent Director |
08/05/2026 |
| Ms. Lota S. Zoth, C.P.A. |
Independent Director |
08/05/2026 |
| Dr. William Grossman, M.D.,PhD |
Independent Director |
08/05/2026 |
| Mr. Philip Astley-Sparke |
Independent Director |
08/05/2026 |
| Mr. Michael T. Heffernan, R.Ph. |
Independent Director |
08/05/2026 |
| Mr. Wouter Joustra |
Independent Director |
08/05/2026 |
|
|
|
|
